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The aims of this study were to identify prognostic variables for toxicity and survival in patients with cancer participating in phase I
clinical trials and compare characteristics of those treated with cytotoxic chemotherapy (CT) and non-cytotoxic drugs (non-CT).
Data were collected from 420 (114 CT, 306 non-CT) patients enrolled in 16 phase I trials (five CT and 11 non-CT trials) in one
cancer centre. Analyses of all patients were used to compare treatment groups, identify predictive variables for toxicity and to
estimate prognostic factors in overall survival (OS). These were used to develop a prognostic index (PI). Multivariate analysis found
those patients with better performance status, fewer sites of metastases, baseline Hb412gdl
 1 and WBC or LDH in the normal
range had significantly better OS. Male gender, platelet count o450 10
9l
 1, high WBC or treatment with a non-CT phase I agent
significantly reduced the chance of grade 3/4 toxicity. Overall survival was not significantly different between the CT and non-CT
groups (260 vs 192 days, P¼0.47) except for those with liver metastases (228 vs 137 days, P¼0.02). Overall tumour response was
4.9% (95% CI: 2.7–7.0%). The PI identified three distinct patient groups with median survival of 321, 257 and 117 days. In conclusion,
entry into a phase I trial of a non-CT drug is a safe option for heavily pretreated patients with cancer. The PI generated from these
data can estimate the survival probability for patients entering phase I studies.
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Careful phase I clinical trial design includes avoidance of
unacceptable toxicity to participating patients with cancer and
minimisation of the number of patients treated with ineffective
drug doses. Despite the need for the development of new therapies,
and the importance attached to the findings of phase I trials in
oncology, surprisingly little information is published about patient
selection and potential prognostic indices that may aid the
clinician in predicting, and discussing, the likely outcome for an
individual. Increasingly, with the development of biological
therapies there is a need to evaluate patient outcome in phase I
studies with newer agents in comparison to those treated with
traditional cytotoxic drugs. This is important for determining
whether or not these trials can be considered as an ethical
treatment option or whether they compromise survival and quality
of life.
Typically, in oncology, phase I trials have been offered to
patients with cancer who have a good performance status and have
either failed standard treatment or for whom no standard therapy
exists. Despite the emphasis on evaluation of side effects, and
determination of a maximum tolerated dose (MTD), tumour
responses remain an important secondary end point. Reported
response rates for phase I trials are generally between 1 and 10%
(Estey et al, 1986; Decoster et al, 1990; Bachelot et al, 2000) with
most responses seen at 80–120% of the recommended phase II
dose (Von Hoff and Turner, 1991). Cytotoxic drugs that do not
show antitumour activity in phase I trials rarely undergo further
evaluation (Von Hoff and Turner, 1991; American Society of
Clinical Oncology, 1997; Sekine et al, 2002).
Previous reviews of phase 1 study data have used multivariable
analyses to explore factors associated with toxicity and prognosis.
Dosage level and age over 65 years are independently associated
with grade 3 or 4 toxicity (Bachelot et al, 2000). Poor performance
status (WHO grade 2 or 3) (Janisch et al, 1994; Bachelot et al,
2000), elevated lactate dehydrogenase (Bachelot et al, 2000), lower
albumin, elevated platelet counts and previous cisplatin therapy
(Janisch et al, 1994) have all been identified as independent
adverse prognostic variables. Analyses have mostly been limited by
small sample sizes and have not compared cytotoxic (CT) with
non-cytotoxic (non-CT) drugs. For new non-CT agents such as
antiangiogenic drugs or matrix metalloproteinase inhibitors,
tumour shrinkage may be less likely and chronic drug adminis-
tration might be required before side effects become apparent.
Careful patient selection is therefore important to maximise the
information obtained from these clinical trials.
In this retrospective study, we compared patients from a single
centre entered into phase I studies with CT drugs or non-CT drugs.
A range of clinical, biochemical and haematological factors were
assessed by both univariate and multivariate analysis for toxicity
and to provide prognostic indicators that could be used for
development of a predictive model for survival in patients entered
into phase I studies.
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Patients
We identified 16 (CT drugs: five; non-CT drugs: 11) phase I clinical
trials conducted by the Cancer Research UK Medical Oncology
Unit, Oxford, between 1991 and 2000 (Table 1). A total of 420
individual patient records and case report forms were used as the
data source. Information collected included demography, perfor-
mance status, diagnosis, stage, number/sites of metastases,
previous therapy, haematological and biochemical indices, start/
end date of study drug treatment, dose level, toxicity grades, date
last seen and date of death. Tumour response was assessed by
WHO (Miller et al, 1981), or South West Oncology Group (SWOG)
criteria (Green and Weiss, 1992) according to the phase I study
protocol. Toxicity was assessed by the NCI-CTC criteria (National
Cancer Institute: Guidelines, 1988). When required by the
individual trial protocol, radiological review was performed by
an independent review panel. In other cases, tumour response was
reported by an independent consultant radiologist blinded to the
treatment intervention. All studies were conducted in accordance
with the Declaration of Helsinki and were approved by Cancer
Research UK and the local research ethics committee.
Statistical methods
Contingency tables were analysed using the Pearson’s w
2 test. The
survival was measured from the first day of treatment on the phase
I trial to the time of death or the time of last follow-up. The log-
rank test was used to perform univariate analysis for survival and
the survival curves were estimated by the Kaplan–Meier method.
Prognostic factors for survival were evaluated in multivariate
analyses by Cox proportional hazards regression. Logistic regres-
sion was performed for estimating the predictors of grade 3/4
toxicity in multifactorial analysis. All statistics were performed
using the Stata package release 7.0 (Stata Corporation, TX, USA).
Based on the five risk factors from the multivariate survival model,
we generated a prognostic index as a survival probability estimator
(S(t)¼exp[-H0(t) exp(PI)], where S(t)¼survival time, H0¼a
step function over time, t¼time, and PI¼prognostic index. The
hazard and estimated survival probability at any time depends
only upon the PI.
RESULTS
Patients
A total of 420 patients (210 males, 210 females), median age 56
years (range 22–87 years) were included in the analysis. The
cancer types reflect referral patterns to the Oxford Medical
Oncology Unit, with the majority of patients having colorectal
(78), melanoma (65), breast (45), renal (39), ovarian (38) and lung
(37) cancers as their primary tumour site. The overall response
rate for all patients was 4.9% (0.3% complete response, 4.6%
partial response) with 19.2% patients obtaining disease stabilisa-
tion for 3 months or longer.
Comparison of CT and non-CT groups
In all, 306 patients were treated with non-CT drugs and 114 with
CT (Table 2). The median age was slightly lower for patients
receiving CT drugs (55 vs 58 years; P¼0.04, Mann–Whitney U-
test), although more patients had a performance status of zero in
the non-CT trials (P¼0.02, Fisher’s exact test). Significantly, more
women were treated with CT drugs (Po0.001, w
2 test) reflecting
inclusion of a study of a novel schedule of cyclophosphamide,
methotrexate and infusional 5-FU for women with breast cancer
(O’Byrne et al, 1998). There was no significant difference in the
numbers of sites of metastases between groups (P¼0.2, w
2 test)
but significantly more patients in the CT studies had liver
metastases (Po0.001, w
2 test). Objective tumour response rates
were higher in patients receiving CT therapy (Po0.001, w
2 test).
The median duration of time on trial was shorter for patients
receiving non-CT treatment (51 vs 73 days, Po0.001, Mann-
Whitney U-test). There was no significant difference in the median
overall survival (192 days (range 4–2405), non-CT vs 260 days
(range 10–1136), CT; P¼0.47, Log-rank test) and no difference in
the numbers of patients who had died within 3 months of study
start (20.6% non-CT vs 16% CT). However, in patients with liver
metastases (n¼127), treatment with CT drugs resulted in a
significant survival advantage compared to non-CT drugs (median
228 vs 137 days, P¼0.02, log-rank test). There was no difference in
survival between groups for patients with lung metastases.
Survival analysis
When all patients were analysed together by univariate analyses,
WHO performance status41, white blood count above the normal
range, low haemoglobin (o12gdl
 1), raised platelets
(4450 10
9l
 1), lactate dehydrogenase above the normal range,
low albumin, number of metastatic sites41, presence of liver and/
or lung metastases and stage of disease were all significant adverse
factors for predicting reduced survival (Table 3). Tumour type and
treatment with either CT or non-CT drugs were not significant
predictors of survival. Data on serial weight change were not
available from the majority of studies and could not be included in
the analysis. In multivariate analysis, only five factors remained as
independent prognostic variables–performance status, white
blood count, haemoglobin, lactate dehydrogenase and the number
of metastatic sites (Table 4). These factors were used for
development of a prognostic index as a predictive model for
survival (see Discussion).
Analysis of toxicity
In univariate analyses for grade 3 or 4 toxicity, treatment with CT
or non-CT drugs, gender, performance status and baseline
creatinine, albumin and age were all significant factors (Table 5).
Haematological indices, lactate dehydrogenase, dose level and
disease stage were not significant. In multivariate analysis, the
class of drug, elevated platelet count, low white blood count and
Table 1 Phase I trials included in analysis
Investigational agent/
molecular target
Number of
patients Reference
Non-cytotoxic
Matrix metalloproteinase inhibitor 9 In preparation
Matrix metalloproteinase inhibitor 6 Macaulay et al (1999)
Mitochondrial inhibitor 11 Propper et al (1999)
Matrix metallo-proteinase inhibitor 92 Levitt et al (2001)
8-Chloro cyclic AMP 33 Propper et al (1999)
Antiangiogenesis 50 Jones et al (1999)
Dendritic cell therapy 5 Chao et al (2003)
Gene therapy 23 Unpublished
EGFR inhibitor 5 Twelves et al (2002)
Protein kinase C partial agonist 56 Philip et al (1993)
Retinoid 16 Jones et al (2003)
Cytotoxic
Topoisomerase I/II inhibitor 12 Propper et al (2003)
Topoisomerase I inhibitor 35 Braybrooke et al (2003)
Topoisomerase I inhibitor 21 Submitted for publication
Bio-modulation of 5-FU 21 Braybrooke et al (2000)
Cyclophosphamide, methotrexate
and infusional 5-FU
25 O’Byrne et al (1998)
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(Table 6).
DISCUSSION
The continued development of new anticancer drugs is dependent
upon patient entry into phase I clinical trials. Treating physicians
have an ethical and moral responsibility to be sure that they do not
compromise patient survival or expose patients to unacceptable
toxicity. Equally, while not the primary end point of phase I
studies, individual trials have limited statistical powers and
potentially beneficial therapies should not be rejected without
thorough assessment. This retrospective analysis of 420 patients,
treated in 16 phase I studies, is the first to address whether there
are differences in outcome for patients entered into CT and non-
CT phase I trials. Conventional multivariate analyses were used to
elucidate which factors appear to be important for predicting
toxicity and survival. The extent to which physician bias may have
influenced patient entry into studies has not been determined in
the analysis but must be considered. All patients were treated at a
single institution, by three physicians, using agreed shared
protocols to minimise bias.
Not surprisingly, treatment with a CT drug as opposed to a non-
CT agent was an independent variable for predicting grade 3 or 4
toxicity. Traditional phase I design includes dose escalations, by
cohort, until significant toxicities are observed. With studies of
non-CT agents, conventional criteria for achieving a maximum
tolerated dose are not always achieved. This may account for the
lack of significance of dose level for predicting grade 3/4 toxicity.
Other factors that did predict toxicity included a low white blood
count, platelet count above the normal range and female sex.
Haematological indices provide nonspecific markers of inflamma-
tory changes and thus may be expected to predict for toxicity. A
low white blood count may also reflect extensive prior cytotoxic
treatment or an immunocompromised patient. Gender was an
unexpected predictor. A report of patients with colorectal cancer
found greater 5-fluorouracil (5-FU)-induced toxicity in women
(Sloan et al, 2002). In our analysis, data from a phase I study of
cyclophosphamide, methotrexate and infusional 5-FU in breast
cancer patients was included. However, if this study is excluded the
toxicity results remain significant. Female gender is also a
significant factor for toxicity in non-CT trials. This may be due
to patients with breast or ovarian cancer entering phase I trials
after extensive previous cytotoxic chemotherapy and radiotherapy.
The large number of trials of different agents, with multiple
mechanisms of action, suggest to us that physiological factors are
unlikely to account for the increased grade 3/4 toxicity in females
although this cannot be ruled out.
One of the aims of this analysis was to determine if there is a
difference in outcome between CT and non-CT phase I trials.
Direct comparison from data in this analysis has been restricted by
Table 2 Comparisons between CT and non-CT groups
Variable Non-cytotoxic Cytotoxic P-value (test)
Number of patients 306 114
Female Total 210 131 (42.8%) 79 (69.3%) o0.001
Male Total 210 175 (57.2%) 35 (30.7%) (w
2)
Median age (range) 58 (22–87) 55 (26–76) 0.04 (M–W)
WHO performance status
0 143 (48.2%) 35 (31.5%)
1 118 (39.7%) 61 (55.0%) 0.02
2 33 (11.1%) 14 (12.6%) (Fisher’s)
3 3 (1.0%) 1 (0.9%)
Number of metastatic sites
0–1 142 (48.6%) 47 (41.6%) 0.20
X2 150 (51.4%) 66 (58.4%) (w
2)
Lung involvement
No 221 (73.7%) 75 (65.8%) 0.11
Yes 79 (26.3%) 39 (34.2%) (w
2)
Liver involvement
No 228 (75.0%) 63 (55.3%) o0.001
Yes 76 (25.0%) 51 (44.7%) (w
2)
Median overall survival, days (range) 192 (4–2405) 260 (10–1136) 0.47 (LR)
Number of deaths at 3 months (%) 63 (20.6%) 18 (16%)
Median overall survival (days)
Liver involvement
No 235 260 0.86 (LR)
Yes 137 228 0.02 (LR)
Lung involvement
No 202 271 0.40 (LR)
Yes 162 228 0.83 (LR)
Median duration of trial (days) 51 73 o 0.001 (M–W)
Response to treatment: (overall)
CR (0.3%) 0 1 (0.9%)
PR (4.6%) 3 (1.0%) 15 (13.2%) o 0.001
SD (19.2%) 42 (13.7%) 36 (31.6%) excluding NE
PD (64.8%) 221 (72.2%) 55 (48.2%) (Fisher’s)
NE (11.1%) 40 (13.1%) 7 (6.1%)
Lactate dehydrogenase
normal range 165 (56.1%) 67 (75.3%) 0.001
4normal range 129 (43.9%) 22 (24.7%) (w
2)
M–W¼Mann–Whitney U-test; Fisher’s¼Fisher’s exact t-test; LR¼log-rank test; w
2¼chi-squared test; CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease; NE¼not evaluable. All responses assessed using standard WHO criteria.
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(114 vs 306 patients respectively). Initial observations on patient
demographics found significantly more women and patients with
liver metastases received CT drugs while more patients with an
initial performance status of zero were entered into studies with
non-CT drugs. These differences may indicate that oncologists are
selective about which trials are offered to patients. Alternatively,
patients considering entry into a phase I trial are selective about
which drugs they prefer to receive, based on perceived efficacy or
toxicity. A previous study on perceptions of patients entering
phase I trials suggested that many were strongly motivated by the
hope of therapeutic benefit (Daugherty et al, 1995) and, if offered a
choice of studies, may consider this carefully.
Tumour response and survival were secondary end points in
every phase I trial conducted. In this study, more patients obtained
an objective tumour response and disease stabilisation when
treated with a CT drug compared to a non-CT drug (14.1% vs 1.0%
and 31.6% vs 13.7%, respectively). The high response rates seen
with CT drugs reflects the inclusion of two phase I trials of novel
schedules of drugs known to have significant antitumour activity
(i.e. cyclophosphamide, methotrexate and infusional 5-FU; 5-FU,
folinic acid and interferon). Subanalysis of response rates in the
phase I studies of novel CT drugs, excluding these two trials, still
showed a partial response rate of 10.3%, which is higher than many
previous reports (Estey et al, 1986; Decoster et al, 1990; Bachelot
et al, 2000; Sekine et al, 2002). Several of these drugs were new
selective topoisomerase inhibitors and would be predicted to have
antitumour activity. Tumour type was not a significant predictor
of outcome in this analysis, although numbers of patients with
each cancer site were small. It is not clear why patients in phase I
Table 3 Univariate survival analysis, all patients
Variable Median OS (days) No. of patients Event (deaths) Log-rank, P-value
Performance status: (WHO)
0 292 178 125 o0.001
X1 154 230 165
White blood count
Normal range 228 364 256 o0.001
4Normal range 120 51 37
Haemoglobin
p12gdl
 1 154 195 147 o0.001
412gdl
 1 293 220 220
Lactate dehydrogenase Normal range 281 232 169 o0.001
4Normal range 137 151 106
Platelets
p450 10
9l
 1 246 362 250 o0.001
4450 10
9l
 1 105 55 43
Stage
2 or 3 468 22 16 0.01
4 193 375 272
Lung/liver involved No 249 207 125 0.03
Yes 189 207 165
Albumin
Low 162 173 120 o0.001
High 249 229 159
Drug Non-cytotoxic 192 306 216 0.47
Cytotoxic 260 114 80
Number of sites of metastases 0–1 264 189 116 0.003
X2 186 216 167
Table 4 Multivariate survival analysis, all patients
Variable Hazard ratio 95% CI P-value
Performance Status (WHO)
0 Baseline
X1 1.48 1.15–1.92 0.003
White blood count
normal range Baseline
above normal range 1.65 1.13–2.40 0.01
Haemoglobin
412gdl
 1 Baseline
p12gdl
 1 1.60 1.23–2.08 o0.001
Lactate dehydrogenase
Normal range Baseline
4Normal range 1.54 1.18–2.01 0.002
Number of sites of metastases
0–1 Baseline
X2 1.5 1.16–1.93 0.002
Table 5 Univariate analysis for WHO grade 3/4 toxicity , all patients
Variable
Odds
ratio
Toxicity
grade o3
Toxicity
grade 3/4 P-value
Treatment
Non-cytotoxic drugs Baseline 191 107 o0.001
Cytotoxic drugs 2.95 43 71
Sex
Female Baseline 94 111 o0.001
Male 0.41 140 67
Performance status (WHO)
0 Baseline 114 64 0.01
X1 1.69 115 109
Creatinine (range)
Lower Baseline 64 74
Middle 0.62 81 58 0.006
Upper 0.46 87 46
Age (Years)
o65 Baseline 163 141 0.03
X65 0.6 71 37
Albumin
Normal range Baseline 87 83 0.03
4Normal range 0.63 141 85
Prognostic indices in phase I trials
C Han et al
1169
British Journal of Cancer (2003) 89(7), 1166–1171 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lstudies of CT drugs remained on trial medication for significantly
longer (73 vs 51 days). Disease progression was the usual reason
for discontinuing treatment. Disease response and stabilisation
favoured patients receiving CT rather than non-CT drugs. It is
possible that patients treated with cytotoxic agents stayed on study
longer because they responded or had stable disease. While higher
response rates were seen with CT drugs, there was no statistically
significant difference in patient survival between the classes of
drugs (260 vs 192 days, P¼0.47). This finding should be
interpreted with caution. More patients with a performance status
of zero entered studies with non-CT drugs (48.2% of patients vs
31.5% of patients in CT trials, P¼0.02) and survival may,
therefore, reflect the natural history of the cancer rather than an
effect of treatment. However, when groups were matched for
performance status there was still no significant difference
(P¼0.45), although numbers of patients were small. Analysis
of patients with liver metastases found that those treated with
a non-CT drug had poorer survival compared to those treated
with a CT drug (137 vs 228 days, Po0.02). This may be of
importance when considering the choice of phase I study although
must be considered with caution, as only 127 patients were
included with liver metastases. The extent of liver disease was not
known.
No comparable data set exists for survival of patients who
elected not to enter phase I trials. Thus, assessment of how entry
into phase I trials affects survival in this patient population cannot
be made. It would seem unlikely, based on the toxicity data, that
participation in a phase I clinical trial compromised survival. The
impact on quality of life is not known.
Establishing independent prognostic indices for survival of
patients treated in phase 1 studies makes it possible to develop a
predictive model for the likely survival of individual patients.
The five factors we identified in this analysis were: performance
status (zero vs one or greater), white blood count (normal range
vs above normal range), haemoglobin (less than or equal to
12gdl
 1 vs greater than 12gdl
 1), lactate dehydrogenase
(normal range vs above normal range) and number of sites of
metastases (zero or one vs two or more sites). These risk factors
can be used to identify whether patients have a good, intermediate
or poor risk of survival (Table 7, Figure 1). Independent analysis
shows a significant difference between each group for survival,
ranging from a median of 321 days for the good risk group to 117
days for the poor risk group. Prognostic factors for individual
patients can be entered into this model and median survival
estimated.
Of the 16 phase I studies included in uni- and multivariable
analyses, two studies employed ‘standard’ chemotherapy adminis-
tered in a novel schedule or in combination with biological
modulators. These potentially more effective treatments might
therefore have biased the results of this study. Exclusion of these
two studies, from the comparisons of CT and non-CT phase I
trials, univariables and multivariable analyses did not significantly
affect the statistical results.
The development of prognostic indices for toxicity and survival
are important considerations in the design of early phase clinical
trials. This retrospective analysis is the first to be reported, that
directly considers phase I non-CT trials. Differences were
identified in baseline characteristics of patients entered into non-
CT phase I studies compared to CT trials. It is not clear whether
this is due to physician bias or patient choice. Most importantly,
no significant difference in median overall survival was found
between the two treatment groups. The use of prognostic models,
as proposed from this analysis, may be important for discussing
patient entry into trials and could, in future, be helpful as part of
the inclusion criteria. The model developed in this study uses five
independent factors and further work, with other large data sets
from phase 1 trial centres, is required for validation and
determination of its use prospectively.
Table 6 Multivariate analysis for WHO toxicity grade 3/4
Variable Hazard ratio 95% CI P-value
Drug
Non-cytotoxic Baseline
Cytotoxic 2.65 1.66–4.24 o0.001
Platelet
p450 10
9l
 1 Baseline
4450 10
9l
 1 2.17 1.14–4.13 0.02
Sex
Female Baseline
Male 0.48 0.31–0.73 o0.001
White blood count
Low Baseline
Middle 0.66 0.40–1.10 0.11
High 0.52 0.31–0.89 0.02
Table 7 Prognostic model for prediction of survival
Formula
S(t)¼exp[-H0(t) exp(PI)]
S(t)¼suvival probability at time t
H0¼a step function over time
PI¼prognostic index
Group
Risk factors
(n)
Patients
(n)
Events
(n)
Median
survival
(days)
Good risk 0–1 136 91 321
Intermediate risk 2 96 64 257
Poor risk X3 127 105 117
Log-rank test:
Overall: Po 0.001
Good vs Intermediate P¼0.004
Intermediate vs poor P o0.001
Good vs poor Po0.001
Patients were divided into three groups depending upon the number of adverse risk
factors (i.e performance status41, white blood count4normal range, haemoglobin
o12gdl
 1, lactate dehydrogenase above normal range, number of sites of
metastases42). Each risk factor counts as 1.
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Figure 1 Predicted survival for patients entered into phase I clinical trials
using independent prognostic indices identified from multivariate analysis
(performance status, white blood count, haemoglobin, lactate dehydro-
genase and number metastastic sites). Patients are categorised into good (0
or 1 risk factors), intermediate (2 risk factors) or poor risk (X3 risk factors).
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